(Q33739817)

29 July 2017

title

Depigmentation therapies for normal skin in vitiligo universalis (English)

1 reference

29 July 2017

1 reference

K M AlGhamdi

1

1 reference

29 July 2017

A Kumar

series ordinal

2

1 reference

29 July 2017

publication date

4 November 2010

1 reference

Journal of the European Academy of Dermatology and Venereology

29 July 2017

published in

1 reference

29 July 2017

volume

25

1 reference

29 July 2017

issue

7

1 reference

29 July 2017

page(s)

749-757

1 reference

Analysis of mammalian pigmentation at the molecular level

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Depigmentation of melanocytes by (2Z,8Z)-matricaria acid methyl ester isolated from Erigeron breviscapus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Vitiligo: compendium of clinico-epidemiological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Psychosocial effects of vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

A survey of vitiligo management among dermatologists in Saudi Arabia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Guideline for the diagnosis and management of vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Chemical and instrumental approaches to treat hyperpigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Mechanism of pigment-cell toxicity produced by hydroxyanisole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Guidelines for the treatment of vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Dermatitic and pigmentary reactions to monobenzyl ether of hydroquinone: report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

A New Formula for Depigmenting Human Skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Enhancement of the depigmenting effect of hydroquinone and 4-hydroxyanisole by all-trans-retinoic acid (tretinoin): the impairment of glutathione-dependent cytoprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Topical treatment of melasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Melanin pigmentary disorders: treatment update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

The histologic evaluation of pulsed carbon dioxide laser resurfacing versus phenol chemical peels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Survey and mechanism of skin depigmenting and lightening agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Contact hypersensitivity to monobenzyl ether of hydroquinone used to treat vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Laser treatment for further depigmentation in vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Comparison of the Q-switched alexandrite, Nd:YAG, and ruby lasers in treating blue-black tattoos

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Q-switched alexandrite laser treatment (755 nm) of professional and amateur tattoos

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Clinical and histological effect of a single treatment of normal mode alexandrite (755 nm) laser on small melanocytic nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

A retrospective study on the efficacy and complications of Q-switched alexandrite laser in the treatment of acquired bilateral nevus of Ota-like macules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Neodymium:yttrium-aluminum-garnet laser for the treatment of cutaneous lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Combination visible and infrared lasers for skin rejuvenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Complications of cutaneous cryosurgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imatinib mesylate causes hypopigmentation in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imatinib mesylate causes hypopigmentation in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod in basal cell carcinoma: how does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Management of nonmelanoma skin cancer in 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Evidence for an autoimmune pathogenesis of vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod: a cytokine inducer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod for the treatment of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

The role of topical immune response modifiers in skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod induces apoptosis of human melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Liposome preparations: a step forward in topical drug therapy for skin disease? A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Imiquimod-induced vitiligo-like depigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

21 January 2018

Depigmentation therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2010.03876.X

10.1111/J.1468-3083.2010.03876.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference